Table 1. Pathological and clinical... | American Society of Hematology

Table 1.

Pathological and clinical features of 20 LBCL cases with IRF4 rearrangement

Case	Age (y), gender	Biopsy site	Growth pattern	Immunohistochemistry				FISH		COO NanoString (Lymph2Cx)	Stage*	Treatment	Outcome, follow-up
Case	Age (y), gender	Biopsy site	Growth pattern	CD10	BCL6	BCL2	IRF4/MUM1	IRF4	IGH	COO NanoString (Lymph2Cx)	Stage*	Treatment	Outcome, follow-up
D1	5, F	LN	Follicular and diffuse	+	+	+	+
D2	14, M	LN	Follicular	+	+	−	+	R		GCB		Surgical excision
D15	5, F	Tonsil	Diffuse	−	+	+	+	R	R	GCB	II	CT-P	CR, 49 mo
D16	14, F	Tonsil	Diffuse	−	+	−	+	R			II	CT-P	CR, 99 mo
D17	21, M	Liver	Diffuse	−	+	+	+	R		ABC	I-E	CT-A	CR, 10 mo †
D20	17, M	Ileum	Diffuse	+	+	+	+	N	R	UNC	II	CT-P	CR, 72 mo
D21	8, M	Tonsil	Follicular	+	+	+	+	R			I	CT-P	CR, 36 mo
D23	21, F	Inguinal LN	Diffuse	−	+		+	R	R	GCB	IV-A	CT-A	CR, 40 mo
D31	12, F	Cervical LN	Diffuse	−	+	+	+	N	R	UNC
D32	7, M	Tonsil	Follicular	+	+	+	+	R		GCB	I	CT-P	CR, 22 mo
D35	6, F	Cervical LN	Diffuse	+	+	−	+	R		GCB	I	CT-P	CR, 63 mo
D46	11, M	Tonsil	Follicular and diffuse	+	+	−	+	R	R	GCB		Surgical excision
D47	22, M	Tonsil	Follicular and diffuse	+	+	−	+	R	R		I	CT-A	CR, 24 mo
D48	18, F	Tonsil	Follicular and diffuse	−	+	−	+	R		UNC	I	CT-A	CR, 29 mo
D50	17, F	Cervical LN	Follicular	−	+	−	+	R	R			Surgical excision
D51	10, F	Tonsil	Follicular and diffuse	+	+	−	+	R		GCB	III	CT-P	CR, 14 mo
D54	18, F	Cervical LN	Diffuse	+	+	+	+	R		GCB	III	CT-P	CR, 14 mo
D62	17, M	Cervical LN	Follicular	−	+	−	+	R		GCB	II	CT-P	CR, 45 mo
D63	14, F	Larynx	Diffuse	+	+	+	+	R		GCB	I	CT-P	CR, 18 mo
D69	15, M	Intestine	Follicular and diffuse	−	+	+	+	R				CT-P	CR, 10 mo

Case	Age (y), gender	Biopsy site	Growth pattern	Immunohistochemistry				FISH		COO NanoString (Lymph2Cx)	Stage*	Treatment	Outcome, follow-up
Case	Age (y), gender	Biopsy site	Growth pattern	CD10	BCL6	BCL2	IRF4/MUM1	IRF4	IGH	COO NanoString (Lymph2Cx)	Stage*	Treatment	Outcome, follow-up
D1	5, F	LN	Follicular and diffuse	+	+	+	+
D2	14, M	LN	Follicular	+	+	−	+	R		GCB		Surgical excision
D15	5, F	Tonsil	Diffuse	−	+	+	+	R	R	GCB	II	CT-P	CR, 49 mo
D16	14, F	Tonsil	Diffuse	−	+	−	+	R			II	CT-P	CR, 99 mo
D17	21, M	Liver	Diffuse	−	+	+	+	R		ABC	I-E	CT-A	CR, 10 mo †
D20	17, M	Ileum	Diffuse	+	+	+	+	N	R	UNC	II	CT-P	CR, 72 mo
D21	8, M	Tonsil	Follicular	+	+	+	+	R			I	CT-P	CR, 36 mo
D23	21, F	Inguinal LN	Diffuse	−	+		+	R	R	GCB	IV-A	CT-A	CR, 40 mo
D31	12, F	Cervical LN	Diffuse	−	+	+	+	N	R	UNC
D32	7, M	Tonsil	Follicular	+	+	+	+	R		GCB	I	CT-P	CR, 22 mo
D35	6, F	Cervical LN	Diffuse	+	+	−	+	R		GCB	I	CT-P	CR, 63 mo
D46	11, M	Tonsil	Follicular and diffuse	+	+	−	+	R	R	GCB		Surgical excision
D47	22, M	Tonsil	Follicular and diffuse	+	+	−	+	R	R		I	CT-A	CR, 24 mo
D48	18, F	Tonsil	Follicular and diffuse	−	+	−	+	R		UNC	I	CT-A	CR, 29 mo
D50	17, F	Cervical LN	Follicular	−	+	−	+	R	R			Surgical excision
D51	10, F	Tonsil	Follicular and diffuse	+	+	−	+	R		GCB	III	CT-P	CR, 14 mo
D54	18, F	Cervical LN	Diffuse	+	+	+	+	R		GCB	III	CT-P	CR, 14 mo
D62	17, M	Cervical LN	Follicular	−	+	−	+	R		GCB	II	CT-P	CR, 45 mo
D63	14, F	Larynx	Diffuse	+	+	+	+	R		GCB	I	CT-P	CR, 18 mo
D69	15, M	Intestine	Follicular and diffuse	−	+	+	+	R				CT-P	CR, 10 mo

CR, complete response; CT-A, chemotherapy with adult schema protocol (R-CHOP/ESHAP); CT-P, chemotherapy with pediatric schema protocol; F, female; LN, lymph node; M, male; N, normal; R, rearrangement; UNC, intermediate/unclassified.

Stage was established according St. Jude/International Pediatric NHL Staging System or Ann Arbor staging system for pediatric and adult patients, respectively.

†

Patients who had a relapse/progression and needed rescue treatment.

View Large

This Feature Is Available To Subscribers Only